Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: A randomized study in patients undergoing autologous peripheral stem cell transplantation

被引:33
作者
Ataergin, Selmin [1 ]
Arpaci, Fikret [1 ]
Turan, Mustafa [1 ]
Solchaga, Luis [2 ,3 ]
Cetin, Turker [4 ]
Ozturk, Mustafa [1 ]
Ozet, Ahmet [1 ]
Komurcu, Seref [1 ]
Ozturk, Bekir [1 ]
机构
[1] GATA Gulhane, Fac Med, Dept Med Oncol & Bone Marrow Transplantat, TR-06018 Ankara, Turkey
[2] Case Western Reserve Univ, Ireland Canc Ctr, Cleveland, OH 44106 USA
[3] Univ Hosp, Cleveland, OH 44106 USA
[4] GATA Gulhane, Fac Med, Dept Hematol, TR-06018 Ankara, Turkey
关键词
D O I
10.1002/ajh.21206
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In vitro studies have demonstrated a 27% increased efficacy of lenograstim over filgrastim. However, equal doses of 10 mu g/kg/day of filgrastim and lenograstim have been recommended for mobilization of CD34+ cells without associated chemotherapy. In this study, we investigated whether a 25% reduced dose of lenograstim at 7.5 mu g/kg/day is equavalent to 10 mu g/kg/day filgrastim for autologous peripheral blood stem cell (PBSC) mobilization and transplantation. A total of 40 consecutive patients were randomized to either filgrastim (n = 20) or lenograstim (n = 20). The two cohorts were similar in regard to disease, sex, body weight, body surface area, conditioning regimens, previous chemotherapy cycles and radiotherapy. Each growth factor was administered for 4 consecutive days. The first PBSC apheresis was done on the 5th day. In the posttransplant period, the same G-CSF was given at 5 mu g/kg/day until leukocyte engraftment. Successful mobilization was achieved in 95% of patients. Successful mobilization with the first apheresis, was achieved in 10/20 (50%) patients in the filgrastim group versus 9/20 (46%) patients in the lenograstim group. No significant difference was seen in the median number of CD34+cells mobilized, as well as the median number of apheresis, median volume of apheresis, percentage of CD34+ cells, and CD34+ cell number. Leukocyte and platelet engraftments, the number of days requiring G-CSF and parenteral antibiotics, the number of transfusions were similar in both groups in the posttransplant period. Lenograstim 7.5 mu g/kg/day is as efficious as filgrastim 10 mu g/kg/day for autologous PBSC mobilization and transplantation.
引用
收藏
页码:644 / 648
页数:5
相关论文
共 22 条
[1]   Peripheral blood progenitor cell (PBPC) mobilization in heavily pretreated patients with germ cell tumors: a report of 34 cases [J].
Dazzi, C ;
Cariello, A ;
Rosti, G ;
Monti, G ;
Sebastiani, L ;
Argnani, M ;
Nicoletti, P ;
Tienghi, A ;
Leoni, M ;
Fiorentini, G ;
Turci, D ;
Giovanis, P ;
De Giorgi, U ;
Marangolo, M .
BONE MARROW TRANSPLANTATION, 1999, 23 (06) :529-532
[2]   Prospective randomized study comparing the efficacy of bioequivalent doses of glycosylated and nonglycosylated rG-CSF for mobilizing peripheral blood progenitor cells [J].
deArriba, F ;
Lozano, ML ;
Ortuno, F ;
Heras, I ;
Moraleda, JM ;
Vicente, V .
BRITISH JOURNAL OF HAEMATOLOGY, 1997, 96 (02) :418-420
[3]  
Decleva E, 1995, INT J TISSUE REACT, V17, P191
[4]   A THERMODYNAMIC MODEL FOR DENATURATION OF GRANULOCYTE-COLONY-STIMULATING FACTOR - O-LINKED SUGAR CHAIN SUPPRESSES NOT THE TRIGGERING DEPROTONATION BUT THE SUCCEEDING DENATURATION [J].
HASEGAWA, M .
BIOCHIMICA ET BIOPHYSICA ACTA, 1993, 1203 (02) :295-297
[5]   Glycosylated and non-glycosylated recombinant human granulocyte colony-stimulating factor (rhG-CSF) -: what is the difference? [J].
Höglund, M .
MEDICAL ONCOLOGY, 1998, 15 (04) :229-233
[6]  
Hoglund M, 1997, EUR J HAEMATOL, V59, P177
[7]  
Hoglund M, 1996, BONE MARROW TRANSPL, V18, P19
[8]  
HOLLOWAY CJ, 1994, EUR J CANCER, V30A, pS2
[9]   Peripheral blood stem cell yield in 400 normal donors mobilised with granulocyte colony-stimulating factor (G-CSF): impact of age, sex, donor weight and type of G-CSF used [J].
Ings, Stuart J. ;
Balsa, Carmen ;
Leverett, David ;
Mackinnon, Stephen ;
Linch, David C. ;
Watts, Michael J. .
BRITISH JOURNAL OF HAEMATOLOGY, 2006, 134 (05) :517-525
[10]  
Kishita M., 1992, CLIN REPORT, V26, P221